Repatha Cost 2026: $239 Cash, $573 List, From $5 With Copay

How much does Repatha cost?

Repatha's cost ranges from about $5 a fill with commercial insurance and Amgen's copay card, to $239 a month cash through AmgenNow, to a list price of $572.70 a month, as of October 2026. Repatha (evolocumab) is one of the most effective cholesterol medicines available, and also one of the most confusing to pay for. What you pay depends on which of three paths you take:

1. Commercial insurance plus Amgen's copay card, which can bring the cost down to as little as $5 a fill once your plan approves it
2. Medicare Part D, where your plan's cost-sharing applies and your yearly out-of-pocket spending on covered drugs is capped
3. Cash through AmgenNow, Amgen's direct-to-patient program, which skips insurance entirely

This chart compares a year of cash or list prices.

What is Repatha's list price?

When Amgen launched AmgenNow in October 2025, Repatha's US list price was $572.70 a month, or roughly $6,900 a year (Managed Healthcare Executive). The price stays the same for the every-two-weeks autoinjector and the once-monthly dose. List price is the number the manufacturer sets before insurance, rebates, or discounts. Very few people pay it, but it matters, because it's what you'd pay at a pharmacy counter with no insurance and no program.

Why is Repatha so expensive, and is there a generic?

Repatha is a biologic, a protein made in living cells, and no generic or biosimilar version has reached the US yet. That missing competition largely explains why the price has held. Prices have come down mainly through direct cash programs, such as AmgenNow at $239 a month.

When will generic Repatha be available?

No US launch date for a generic or biosimilar Repatha is public as of October 2026. A copy of a biologic is called a biosimilar, and Amgen's annual report lists US patents covering Repatha's antibodies through August 27, 2029 and its methods of treatment through May 10, 2032 (Amgen 10-K, filed February 2026). Patent dates mark when one barrier ends. A biosimilar maker also needs FDA approval, and no approval or launch date has been announced in the sources we reviewed. Until then, AmgenNow's cash price is the lower-cost way to get Repatha itself.

Is there a Repatha coupon or discount?

Yes, two. People with commercial insurance can use Amgen's copay card, and anyone with a prescription can use the GoodRx coupon that comes with AmgenNow. Details for each follow.

How much is Repatha without insurance? The AmgenNow price

In October 2025, Amgen launched AmgenNow and set Repatha's cash price at $239 a month, nearly 60% below list (Amgen press release). Here's how it works, per the program's own terms (AmgenNow):

• You still need a valid prescription.
• You download a discount coupon through GoodRx and fill it at a participating pharmacy.
• No prior authorization or step therapy is required.
• It's open to everyone, including people with Medicare or Medicaid.

The program comes with conditions, so read them before you choose it. You agree not to submit the cost to your insurer. If you have Medicare Part D or another government plan, you also agree not to count the cost toward your deductible or out-of-pocket limit, and to buy all of that Amgen medicine through the program for the rest of the calendar year.

Who qualifies for the Repatha copay card?

People with commercial insurance qualify once their plan approves Repatha, and the card is not valid with Medicare, Medicaid, or other federal or state programs. If you have insurance through an employer or the marketplace, and your plan approves Repatha, Amgen's copay program can lower your cost to as little as $5 for the first fill and each refill, up to program limits, with no income requirement (Repatha.com).

The copay card helps only after insurance agrees to cover the drug, which usually means prior authorization.

Is Repatha covered by Medicare?

Yes. Medicare Part D plans generally cover Repatha, though the manufacturer copay card can't be used with Medicare, by Amgen's terms. In 2026 you also get:

• The out-of-pocket cap. Once you've spent $2,100 on covered drugs in 2026, your Part D plan pays 100% for the rest of the year (GoodRx).
• Typical cost-sharing. Amgen reports that about 84% of Medicare Repatha prescriptions cost patients $50 or less a month, and people with the Part D Low Income Subsidy may pay $12.65 or less (Repatha.com). Your own cost depends on your plan's tier.

Repatha runs through Part D, the drug benefit, which is where Amgen's Medicare figures above apply. Part B usually covers drugs you get at a doctor's office or hospital outpatient setting (Medicare.gov), so a clinic-given shot like Leqvio usually falls under Part B instead.

Medicare plans usually require prior authorization too, with criteria similar to commercial plans.

How do I get Repatha covered? Prior authorization

Prior authorization means your insurer wants proof that you need the drug before it pays. Criteria vary by plan, but they tend to look alike. As one real example, a 2026 commercial policy from Mass General Brigham Health Plan approves Repatha when a member has a qualifying diagnosis (such as atherosclerotic cardiovascular disease, meaning plaque-related heart or blood vessel disease, or familial hypercholesterolemia) and (MGB Health Plan policy):

• Has taken the highest tolerable statin dose for at least 12 weeks, or couldn't tolerate at least two statins, or can't take statins at all
• Has an LDL cholesterol (LDL-C) of 70 mg/dL or higher with cardiovascular disease, or 100 mg/dL or higher without it, measured within the last 120 days while on that treatment

Other plans also require a documented trial of ezetimibe first. The 2026 ACC/AHA cholesterol guideline no longer insists on ezetimibe before a PCSK9 inhibitor, and recommends adding ezetimibe and/or a PCSK9 inhibitor "without delay" when LDL stays high on a statin (ACC). Plan policies don't always match the newest guideline right away, so follow your plan's own criteria.

What can I do if my insurance denies Repatha?

A denial is often a request for more information. Appeals usually follow this sequence:

1. Read the denial letter. It should say which criterion wasn't met, like a missing LDL-C result or an undocumented statin trial.
2. File an internal appeal with the missing documentation and a letter of medical necessity from your clinician.
3. Ask for an external review if the internal appeal is denied. Under federal law, most health plans must allow an independent third party to review the decision (HealthCare.gov).

Medicare Part D has its own version: a coverage determination, then an exception request or redetermination if needed. Deadlines matter in both systems, so file promptly.

Why Repatha is worth the effort

Repatha has outcomes data, meaning trials that counted heart attacks and strokes on top of cholesterol numbers. In FOURIER, more than 27,000 people with cardiovascular disease on a statin took Repatha or placebo. Repatha lowered LDL by 59% and reduced the combined risk of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, or a procedure to open an artery by 15%.

A newer trial, VESALIUS-CV, found a 25% lower risk of a first heart attack, stroke, or coronary death in high-risk people who had never had one.

Is there a Praluent coupon, and what does Praluent cost?

Praluent has a copay card for commercial insurance. Regeneron's patient brochure says eligible patients may pay as little as $50 a month, with a $3,500 annual cap, and the card excludes Medicare, Medicaid, and other government programs (Praluent patient brochure, November 2025). The same brochure says the free-drug patient assistance program no longer accepts new enrollees or Medicare Part D patients, so only current enrollees can re-enroll. No cash or list price appears in the official Praluent materials we reviewed, so this guide quotes none. Check praluent.com for current card terms, and ask your pharmacy for today's price.

Is there a Leqvio coupon?

Yes, if you have commercial insurance. Novartis's Leqvio Co-pay Program says eligible commercially insured patients may pay as little as $0 (Leqvio.com). Per-treatment maximums and an annual cap apply, though Novartis does not publish the dollar amounts in its terms (Co-pay Program terms). The program excludes Medicare, Medicaid, TRICARE, VA, DoD, and other government programs, and Novartis can change or end it at any time. People with traditional Medicare use Part B instead and owe 20% coinsurance unless a supplemental plan covers it. Your clinic or start.leqvio.com handles enrollment.

How can I pay less for Repatha or a similar drug?

The cheapest route depends on your coverage: the copay card if commercial insurance approves Repatha, AmgenNow if insurance is the obstacle, or a lower-priced drug in the same class.

Use the insurance path if you have good coverage. With commercial insurance and an approved prior authorization, the copay card usually makes this the cheapest option. It takes the most paperwork up front.

Use the cash path if insurance is the obstacle. If your deductible is high, your plan excludes PCSK9 inhibitors, or you don't want to wait on approval, AmgenNow's price is predictable and needs no prior authorization.

Consider a lower-priced drug in the same class. As of October 2026:

• Lipfendra (enlicitide), the first oral PCSK9 inhibitor, launched at a list price of $315 a month (Chicago Sun-Times). See our Lipfendra guide.
• Lerochol (lerodalcibep), a once-monthly injection, has a direct-to-patient cash price of $199 a month (LIB Therapeutics). An autoinjector pen was approved in August 2026 and is expected by January 2027 at the same price (LIB Therapeutics). See our Lerochol guide.
• Leqvio (inclisiran) costs more per dose but is given only twice a year after the first two doses, and Medicare usually covers it under Part B when it's given in a clinic (Leqvio.com; Medicare.gov). See our Leqvio guide.

Neither Lipfendra nor Lerochol has finished an outcomes trial yet, which is a real difference from Repatha. Our guide to Repatha alternatives compares all of them side by side, and PCSK9 inhibitors explained covers how the class works.

How Preval Health helps

Preval Health focuses on prescription cholesterol care. Our treatment protocols are written by a board-certified preventive cardiologist, and licensed clinicians prescribe through our partner telehealth network.

Preval runs as a cash practice: we don't file insurance claims or prior authorizations. A partner clinician writes the prescription, and we connect you with manufacturer direct programs such as AmgenNow. Care costs $99 a month, and you pay the medicine's cash price. If your plan denied Repatha, you can start here. Either way, we recheck your labs every quarter, and your clinician adjusts treatment to your actual numbers. If you want the step-by-step version, see how to get a PCSK9 inhibitor prescription online.